Theresa L Whiteside1,2,3,4, Robert L Ferris1,3,4, Miroslaw Szczepanski4, Mitchell Tublin5, Joseph Kiss6,4, Rita Johnson4, Jonas T Johnson1,4. 1. Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 4. University of Pittsburgh Cancer Institute Hillman Cancer Center, Pittsburgh, Pennsylvania. 5. Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 6. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: An autologous vaccine of apoptotic tumor cells (ATCs) and dendritic cells (DCs) was administered to patients with stage III/IV head and neck squamous cell carcinoma (HNSCC) to study safety and feasibility. METHODS: Autologous DCs were generated from monocytes, loaded with ATCs, and delivered intranodally. Delayed-type hypersensitivity (DTH) and immunological endpoints were measured prevaccination and postvaccination. Clinical follow-up was required. RESULTS: Tumors obtained from 30 patients yielded 2 × 10(6) to 2 × 10(8) tumor cells. Only 19 of 30 (63%) were sterile. Ten of 30 patients (33%) had ≥1 × 10(7) sterile tumor cells required for vaccine production. Eight of 10 patients had positive recall DTH. Five of 10 patients were leukapheresed to generate DCs. Four of 5 patients were vaccinated. ATC-reactive T cells were detected in 3 of 4 patients. All 4 patients survived >5 years. The trial failed to enroll the projected 12 patients and was terminated. CONCLUSION: This vaccine was safe and immunogenic but feasible only in patients with HNSCC with positive prevaccine DTH and ≥1 × 10(7) sterile tumor cells. All vaccinated patients were long-term disease-free survivors.
BACKGROUND: An autologous vaccine of apoptotic tumor cells (ATCs) and dendritic cells (DCs) was administered to patients with stage III/IV head and neck squamous cell carcinoma (HNSCC) to study safety and feasibility. METHODS: Autologous DCs were generated from monocytes, loaded with ATCs, and delivered intranodally. Delayed-type hypersensitivity (DTH) and immunological endpoints were measured prevaccination and postvaccination. Clinical follow-up was required. RESULTS:Tumors obtained from 30 patients yielded 2 × 10(6) to 2 × 10(8) tumor cells. Only 19 of 30 (63%) were sterile. Ten of 30 patients (33%) had ≥1 × 10(7) sterile tumor cells required for vaccine production. Eight of 10 patients had positive recall DTH. Five of 10 patients were leukapheresed to generate DCs. Four of 5 patients were vaccinated. ATC-reactive T cells were detected in 3 of 4 patients. All 4 patients survived >5 years. The trial failed to enroll the projected 12 patients and was terminated. CONCLUSION: This vaccine was safe and immunogenic but feasible only in patients with HNSCC with positive prevaccine DTH and ≥1 × 10(7) sterile tumor cells. All vaccinated patients were long-term disease-free survivors.
Authors: Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: Kent W Mouw; Abhishek A Solanki; Kerstin M Stenson; Mary Ellyn Witt; Elizabeth A Blair; Ezra E W Cohen; Everett E Vokes; Marcy List; Daniel J Haraf; Joseph K Salama Journal: Oral Oncol Date: 2012-05-22 Impact factor: 5.337
Authors: Carsten Schaefer; Lisa H Butterfield; Sandra Lee; Grace G Kim; Carmen Visus; Andreas Albers; John M Kirkwood; Theresa L Whiteside Journal: Int J Cancer Date: 2012-01-11 Impact factor: 7.396
Authors: Andrés López-Albaitero; Jayakar V Nayak; Takeshi Ogino; Avinash Machandia; William Gooding; Albert B DeLeo; Soldano Ferrone; Robert L Ferris Journal: J Immunol Date: 2006-03-15 Impact factor: 5.422
Authors: Kellie N Smith; Robbie B Mailliard; Paolo A Piazza; Will Fischer; Bette T Korber; Ronald J Fecek; Deena Ratner; Phalguni Gupta; James I Mullins; Charles R Rinaldo Journal: mBio Date: 2016-05-31 Impact factor: 7.867